Bradley McGregor, MD, explains how despite major advances in metastatic renal cell carcinoma, there are still patients who do not respond or maintain their initial response to the novel treatment option. Therefore, McGregor, says there remains a need for novel treatment targets and therapies in this space. McGregor is clinical director, Lank Center for Genitourinary Oncology, senior physician, instructor in Medicine, Harvard Medical School, Dana-Farber Cancer Institute.
Updated data show survival benefit with adjuvant pembrolizumab in ccRCC
April 19th 2024“This is the first study to show a statistically significant and clinically meaningful survival improvement with any adjuvant therapy in kidney cancer, and this further supports adjuvant pembrolizumab as a standard of care after surgery in this disease setting,” says Toni K. Choueiri, MD.
Toripalimab plus axitinib approved in China for renal cell carcinoma
April 11th 2024The approval is based on findings from the phase 3 RENOTORCH trial, which showed that toripalimab plus axitinib prolonged progression-free survival and improved the objective response rate in patients with advanced RCC compared with sunitinib.